Trial Outcomes & Findings for Absorb IV Randomized Controlled Trial (NCT NCT02173379)
NCT ID: NCT02173379
Last Updated: 2023-10-30
Results Overview
Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))
COMPLETED
NA
2604 participants
30 days
2023-10-30
Participant Flow
A total of 2604 subjects were randomized at 147 sites between August 15, 2014 and March 31, 2017. The last 5-year follow-up visit occurred on April 06, 2022. The database was then cleaned, and data extraction for the 5-year analysis occurred on July 29, 2022.
The number of All-Cause Mortality will differ from that reported in the Participant Flow module. This is due to the follow-up window 'treatment' of the data. Only deaths that occurred prior to the beginning of the 5-year visit window (Day 1797=1825-28) are counted in the Participant Flow; whereas in the AE table, participants who died within the follow-up window are counted.
Participant milestones
| Measure |
Absorb BVS
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
|
XIENCE
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
|---|---|---|
|
Overall Study
STARTED
|
1296
|
1308
|
|
Overall Study
COMPLETED
|
1099
|
1118
|
|
Overall Study
NOT COMPLETED
|
197
|
190
|
Reasons for withdrawal
| Measure |
Absorb BVS
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
|
XIENCE
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
|---|---|---|
|
Overall Study
Lost to Follow-up
|
89
|
81
|
|
Overall Study
Withdrawal by Subject
|
24
|
29
|
|
Overall Study
Physician Decision
|
8
|
8
|
|
Overall Study
Death
|
75
|
72
|
|
Overall Study
Other Reason
|
1
|
0
|
Baseline Characteristics
The number of participants analyzed includes subjects who were available at that time of analysis
Baseline characteristics by cohort
| Measure |
Absorb BVS
n=1296 Participants
Subjects receiving public) Absorb Bioresorbable Vascular Scaffold (BVS), and the Absorb GT1™ BVS System
|
XIENCE
n=1308 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Total
n=2604 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
63.1 years
STANDARD_DEVIATION 10.1 • n=1296 Participants
|
62.2 years
STANDARD_DEVIATION 10.3 • n=1308 Participants
|
62.65 years
STANDARD_DEVIATION 10.2 • n=2604 Participants
|
|
Sex: Female, Male
Female
|
369 Participants
n=1296 Participants
|
361 Participants
n=1308 Participants
|
730 Participants
n=2604 Participants
|
|
Sex: Female, Male
Male
|
927 Participants
n=1296 Participants
|
947 Participants
n=1308 Participants
|
1874 Participants
n=2604 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
40 Participants
n=1296 Participants
|
29 Participants
n=1308 Participants
|
69 Participants
n=2604 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
0 Participants
n=1296 Participants
|
0 Participants
n=1308 Participants
|
0 Participants
n=2604 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1256 Participants
n=1296 Participants
|
1279 Participants
n=1308 Participants
|
2535 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
4 Participants
n=1296 Participants
|
8 Participants
n=1308 Participants
|
12 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
Asian
|
30 Participants
n=1296 Participants
|
36 Participants
n=1308 Participants
|
66 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
11 Participants
n=1296 Participants
|
4 Participants
n=1308 Participants
|
15 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
Black or African American
|
71 Participants
n=1296 Participants
|
61 Participants
n=1308 Participants
|
132 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
White
|
1135 Participants
n=1296 Participants
|
1160 Participants
n=1308 Participants
|
2295 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=1296 Participants
|
0 Participants
n=1308 Participants
|
0 Participants
n=2604 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
45 Participants
n=1296 Participants
|
39 Participants
n=1308 Participants
|
84 Participants
n=2604 Participants
|
|
Region of Enrollment
Canada
|
28 participants
n=1296 Participants
|
26 participants
n=1308 Participants
|
54 participants
n=2604 Participants
|
|
Region of Enrollment
United States
|
1021 participants
n=1296 Participants
|
1041 participants
n=1308 Participants
|
2062 participants
n=2604 Participants
|
|
Region of Enrollment
Australia
|
80 participants
n=1296 Participants
|
68 participants
n=1308 Participants
|
148 participants
n=2604 Participants
|
|
Region of Enrollment
Germany
|
164 participants
n=1296 Participants
|
171 participants
n=1308 Participants
|
335 participants
n=2604 Participants
|
|
Region of Enrollment
Singapore
|
3 participants
n=1296 Participants
|
2 participants
n=1308 Participants
|
5 participants
n=2604 Participants
|
|
Prior Coronary Intervention
|
390 Participants
n=1294 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
|
435 Participants
n=1307 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
|
825 Participants
n=2601 Participants • The number of participants analyzed includes subjects who were available at that time of analysis
|
PRIMARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Failure (TLF)
|
48 Participants
|
64 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
One-sided p-value by using Farrington-Manning non-inferiority test will be used with non-inferiority margin of 4.8%, to be compared with a one-sided significance level of 0.025.
Outcome measures
| Measure |
XIENCE
n=1272 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1254 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
TLF at 1-year, Non-inferiority Against the Control
|
82 Participants
|
98 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Angina is defined as any angina or angina equivalent symptoms determined by the physician and/or research coordinator after interview of the patient, and as adjudicated by a clinical events committee (CEC). * This analysis will exclude angina or angina equivalent symptoms that occurred following the index procedure through hospital discharge or 7 days, whichever occurs first.
Outcome measures
| Measure |
XIENCE
n=1265 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1248 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Angina at 1-year, Non-inferiority Against the Control
|
494 Participants
|
459 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7days)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Successful delivery and deployment of the study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by quantitative coronary angiography (QCA) (by visual estimation if QCA unavailable). When bailout scaffold/stent is used, the success or failure of the bailout scaffold/stent delivery and deployment is not one of the criteria for device success.
Outcome measures
| Measure |
XIENCE
n=1450 Target lesions
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1424 Target lesions
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Percentage of Target Lesion With Acute Success- Device Success (Lesion Level Analysis)
|
99.0 Percentage of target lesions
|
94.6 Percentage of target lesions
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7days)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days).
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Acute Success- Procedural Success (Subject Level Analysis)
|
1246 Participants
|
1194 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
5 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
8 Participants
|
7 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
11 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
15 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
22 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
32 Participants
|
39 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
49 Participants
|
54 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. For the All-Cause Mortality data, the denominator excludes participants who are lost-to-follow-up or withdrawn (by subject or physician) through a given timepoint without any DMR event (all death, MI and revascularization, respectively). If these participants were included in the denominator in each arm, that would equate to assuming that these participants are alive, potentially underestimating the death rate by inflating the denominator.
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Death (Cardiac, Vascular, Non-cardiovascular)
|
72 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
43 Participants
|
50 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
47 Participants
|
58 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
50 Participants
|
66 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
56 Participants
|
70 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
62 Participants
|
75 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
65 Participants
|
80 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
86 Participants
|
104 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
104 Participants
|
126 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
119 Participants
|
145 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Attributable to target vessel (TV-MI) * Not attributable to target vessel (NTV-MI)
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Myocardial Infarction (MI)
|
134 Participants
|
154 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
43 Participants
|
50 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
47 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
48 Participants
|
63 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
53 Participants
|
67 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
56 Participants
|
71 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
58 Participants
|
75 Participants
|
SECONDARY outcome
Timeframe: 2 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
72 Participants
|
94 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
86 Participants
|
112 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
94 Participants
|
126 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Myocardial Infarction (TV-MI)
|
106 Participants
|
134 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
1 Participants
|
8 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
3 Participants
|
14 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants withTarget Lesion Revascularization (TLR)
|
4 Participants
|
16 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
11 Participants
|
23 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
15 Participants
|
33 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
24 Participants
|
38 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
38 Participants
|
70 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
50 Participants
|
90 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
65 Participants
|
107 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography.
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Revascularization (TLR)
|
82 Participants
|
114 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
1 Participants
|
8 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
3 Participants
|
13 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
4 Participants
|
15 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
11 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
15 Participants
|
32 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
24 Participants
|
37 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
38 Participants
|
67 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
50 Participants
|
87 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
65 Participants
|
104 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TLR is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as ischemia driven or not ischemia driven by the investigator prior to repeat angiography
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Ischemia Driven TLR (ID-TLR)
|
82 Participants
|
111 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
0 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
1 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
6 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. classified as: Ischemic driven TVR and Non-ischemic driven TVR. -TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
14 Participants
|
14 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
16 Participants
|
19 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
20 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
39 Participants
|
44 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
49 Participants
|
67 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
66 Participants
|
82 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Vessel Revascularization (TVR)
|
81 Participants
|
91 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
0 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
1 Participants
|
5 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
6 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
14 Participants
|
14 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
16 Participants
|
19 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
20 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
38 Participants
|
42 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
48 Participants
|
65 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
65 Participants
|
80 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
TVR is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. * TVR includes both Ischemic driven TVR and Non-ischemic driven TVR. * TVR includes all TVR, excluding TLR
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With ID-TVR Excluding TLR
|
80 Participants
|
89 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
4 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
8 Participants
|
19 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
15 Participants
|
28 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
30 Participants
|
41 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
39 Participants
|
54 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
51 Participants
|
64 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
89 Participants
|
117 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
113 Participants
|
157 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
141 Participants
|
185 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Revascularization includes TLR, TVR excluding TLR, and non TVR.
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With All Coronary Revascularization
|
167 Participants
|
198 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
43 Participants
|
51 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
48 Participants
|
59 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
55 Participants
|
69 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
64 Participants
|
74 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
72 Participants
|
80 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
79 Participants
|
89 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
106 Participants
|
116 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
132 Participants
|
150 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
159 Participants
|
181 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
All deaths includes * Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. * Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause. * Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG. -Non-Q wave MI: Those MIs which are not Q-wave MI
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced All Death/All MI
|
188 Participants
|
209 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
43 Participants
|
51 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
47 Participants
|
59 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
53 Participants
|
67 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
61 Participants
|
71 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
68 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
73 Participants
|
83 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
96 Participants
|
107 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
118 Participants
|
133 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
137 Participants
|
157 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI
|
155 Participants
|
171 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
44 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
48 Participants
|
64 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
53 Participants
|
71 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
64 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
71 Participants
|
90 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
83 Participants
|
98 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
107 Participants
|
138 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
134 Participants
|
171 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
153 Participants
|
200 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
|
180 Participants
|
216 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (Major Adverse Cardiac Events-MACE)
|
44 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced With Cardiac Death/All MI/ID-TLR (MACE)
|
48 Participants
|
65 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
55 Participants
|
74 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
67 Participants
|
80 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
77 Participants
|
93 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
89 Participants
|
102 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
121 Participants
|
146 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
152 Participants
|
183 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
178 Participants
|
217 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR).
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR (MACE)
|
207 Participants
|
233 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (Target Vessel Failure, TVF)
|
44 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
48 Participants
|
66 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
59 Participants
|
77 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
75 Participants
|
86 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
86 Participants
|
101 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
101 Participants
|
111 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
139 Participants
|
163 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
171 Participants
|
211 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
203 Participants
|
246 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR).
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Cardiac Death/All MI/ID-TLR/ID-TVR, Non TL (TVF)
|
240 Participants
|
262 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
46 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1303 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
53 Participants
|
67 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1300 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1286 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
65 Participants
|
81 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
82 Participants
|
94 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1279 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1264 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
97 Participants
|
110 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
114 Participants
|
125 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1255 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1236 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
161 Participants
|
185 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1241 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1219 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
198 Participants
|
241 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1220 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1206 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
239 Participants
|
281 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization.
Outcome measures
| Measure |
XIENCE
n=1200 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1189 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants Experienced Death/All MI/All Revascularization (DMR)
|
284 Participants
|
310 Participants
|
SECONDARY outcome
Timeframe: 0 - 24 hours post stent implantationPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).
Outcome measures
| Measure |
XIENCE
n=1305 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1291 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Definite
|
0 Participants
|
3 Participants
|
|
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Definite/Probable
|
0 Participants
|
4 Participants
|
|
Number of Participants With Acute Scaffold/Stent Thrombosis (Per Academic Research Consortium (ARC) Definition)
Probable
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: >24 hours - 30 days post stent implantationPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).
Outcome measures
| Measure |
XIENCE
n=1301 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1287 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
|
2 Participants
|
4 Participants
|
|
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Subacute Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 30 days - 1 year post stent implantationPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (\>24 hours to 30 days post stent implantation), late (\>30 days to 1 year post stent implantation).
Outcome measures
| Measure |
XIENCE
n=1259 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1239 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
|
2 Participants
|
1 Participants
|
|
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Late Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 0 to 730 DaysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained
Outcome measures
| Measure |
XIENCE
n=1232 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1214 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Definite
|
6 Participants
|
11 Participants
|
|
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Definite/Probable
|
6 Participants
|
12 Participants
|
|
Number of Participants With Cumulative Scaffold/Stent Thrombosis (Per ARC Definition)
Probable
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* Coronary artery disease (CAD) related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1302 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
59 Participants
|
66 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1298 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1285 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
122 Participants
|
111 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1291 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
178 Participants
|
178 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1278 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1265 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
237 Participants
|
227 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1271 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1254 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
289 Participants
|
277 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1254 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1238 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
446 Participants
|
443 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1242 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1226 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
525 Participants
|
544 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1226 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1215 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
578 Participants
|
612 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
* CAD related * Cardiovascular, non-CAD related * Non-cardiovascular related
Outcome measures
| Measure |
XIENCE
n=1210 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1205 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Rehospitalization
|
621 Participants
|
654 Participants
|
SECONDARY outcome
Timeframe: In-hospital (≤ 7 days post index procedure)Population: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1304 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1290 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
7 Participants
|
4 Participants
|
SECONDARY outcome
Timeframe: 30 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1301 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1288 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
21 Participants
|
18 Participants
|
SECONDARY outcome
Timeframe: 90 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1295 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1282 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
40 Participants
|
33 Participants
|
SECONDARY outcome
Timeframe: 180 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1284 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1278 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
64 Participants
|
57 Participants
|
SECONDARY outcome
Timeframe: 270 daysPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1270 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1259 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
87 Participants
|
71 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population.The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1260 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1242 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
103 Participants
|
84 Participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1237 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1218 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
161 Participants
|
140 Participants
|
SECONDARY outcome
Timeframe: 3 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1212 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1186 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
188 Participants
|
186 Participants
|
SECONDARY outcome
Timeframe: 4 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1178 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1157 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
220 Participants
|
209 Participants
|
SECONDARY outcome
Timeframe: 5 yearsPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Outcome measures
| Measure |
XIENCE
n=1144 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1125 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Repeat Coronary Arteriography
|
237 Participants
|
225 Participants
|
SECONDARY outcome
Timeframe: 1 yearPopulation: ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
The analysis will be based on 4610 subjects (2000 primary analysis subjects of ABSORB III and 2610 subjects of ABSORB IV)
Outcome measures
| Measure |
XIENCE
n=1273 Participants
Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only)
|
Absorb BVS
n=1255 Participants
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
|
|---|---|---|
|
Number of Participants With Target Lesion Failure (TLF)
|
83 Participants
|
98 Participants
|
Adverse Events
Absorb BVS
XIENCE
Serious adverse events
| Measure |
Absorb BVS
n=1296 participants at risk
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
|
XIENCE
n=1308 participants at risk
Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
|
|---|---|---|
|
Renal and urinary disorders
RENAL FAILURE ACUTE
|
2.1%
27/1296 • 5 years
|
1.7%
22/1308 • 5 years
|
|
Eye disorders
CATARACT
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Investigations
CORONAVIRUS TEST POSITIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
EJECTION FRACTION DECREASED
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Blood and lymphatic system disorders
ANAEMIA
|
0.85%
11/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
HAEMORRHAGIC ANAEMIA
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Blood and lymphatic system disorders
IRON DEFICIENCY ANAEMIA
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Blood and lymphatic system disorders
NORMOCHROMIC NORMOCYTIC ANAEMIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Blood and lymphatic system disorders
PANCYTOPENIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ACUTE CORONARY SYNDROME
|
0.77%
10/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Cardiac disorders
ACUTE LEFT VENTRICULAR FAILURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
|
1.8%
23/1296 • 5 years
|
2.0%
26/1308 • 5 years
|
|
Cardiac disorders
ANGINA PECTORIS
|
10.4%
135/1296 • 5 years
|
8.6%
113/1308 • 5 years
|
|
Cardiac disorders
ANGINA UNSTABLE
|
4.1%
53/1296 • 5 years
|
4.4%
57/1308 • 5 years
|
|
Cardiac disorders
AORTIC VALVE INCOMPETENCE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
AORTIC VALVE STENOSIS
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
ARRHYTHMIA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
ARTERIOSCLEROSIS CORONARY ARTERY
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
ARTERIOSPASM CORONARY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
3.5%
45/1296 • 5 years
|
2.4%
32/1308 • 5 years
|
|
Cardiac disorders
ATRIAL FLUTTER
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
ATRIAL TACHYCARDIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ATRIAL THROMBOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK COMPLETE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK SECOND DEGREE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
BRADYCARDIA
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
BUNDLE BRANCH BLOCK LEFT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIAC ARREST
|
0.77%
10/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE
|
1.0%
13/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE ACUTE
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE CHRONIC
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE CONGESTIVE
|
1.9%
24/1296 • 5 years
|
1.8%
23/1308 • 5 years
|
|
Cardiac disorders
CARDIAC PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIAC TAMPONADE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIAC VALVE DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIO-RESPIRATORY ARREST
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
CARDIOGENIC SHOCK
|
0.39%
5/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIOMYOPATHY
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIOPULMONARY FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CHRONOTROPIC INCOMPETENCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CONGESTIVE CARDIOMYOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
COR PULMONALE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY DISEASE
|
3.5%
45/1296 • 5 years
|
3.0%
39/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY DISSECTION
|
3.2%
41/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY EMBOLISM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY OCCLUSION
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY PERFORATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY STENOSIS
|
1.1%
14/1296 • 5 years
|
1.1%
15/1308 • 5 years
|
|
Cardiac disorders
HYPERTENSIVE HEART DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
HYPERTROPHIC CARDIOMYOPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
IN-STENT CORONARY ARTERY RESTENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
INTRACARDIAC THROMBUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
INTRAPERICARDIAL THROMBOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ISCHAEMIC CARDIOMYOPATHY
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE INCOMPETENCE
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
MYOCARDIAL INFARCTION
|
5.2%
67/1296 • 5 years
|
4.1%
54/1308 • 5 years
|
|
Cardiac disorders
MYOCARDIAL ISCHAEMIA
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
MYOCARDITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
MYOPERICARDITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
PALPITATIONS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
PERICARDIAL EFFUSION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
PERICARDIAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
PERICARDITIS
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
PRINZMETAL ANGINA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
PULSELESS ELECTRICAL ACTIVITY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
SICK SINUS SYNDROME
|
0.39%
5/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
STRESS CARDIOMYOPATHY
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
SUPRAVENTRICULAR TACHYCARDIA
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
TACHYCARDIA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
TRICUSPID VALVE INCOMPETENCE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR EXTRASYSTOLES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR FIBRILLATION
|
0.39%
5/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR TACHYCARDIA
|
0.23%
3/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Congenital, familial and genetic disorders
ARTERIOVENOUS MALFORMATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
ATRIAL SEPTAL DEFECT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
CORNEAL DYSTROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
GASTROINTESTINAL ARTERIOVENOUS MALFORMATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Congenital, familial and genetic disorders
HYDROCELE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
PERONEAL MUSCULAR ATROPHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Congenital, familial and genetic disorders
PHIMOSIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Congenital, familial and genetic disorders
URACHAL ABNORMALITY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
VERTIGO
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Ear and labyrinth disorders
VERTIGO POSITIONAL
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Endocrine disorders
ADRENAL INSUFFICIENCY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Endocrine disorders
CARCINOID SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
GOITRE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPERPARATHYROIDISM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPOTHYROIDIC GOITRE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
THYROID MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
AMAUROSIS FUGAX
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Eye disorders
DIPLOPIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
GLAUCOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Eye disorders
MACULAR FIBROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL ARTERY EMBOLISM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL DETACHMENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
TOLOSA-HUNT SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
VITREOUS HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL HERNIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.54%
7/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN LOWER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ANAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ASCITES
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
BARRETT'S OESOPHAGUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
CHRONIC GASTROINTESTINAL BLEEDING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS
|
0.54%
7/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS ISCHAEMIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS ULCERATIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
COLONIC POLYP
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
CONSTIPATION
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Gastrointestinal disorders
CROHN'S DISEASE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DENTAL CARIES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DIARRHOEA
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULAR PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULITIS INTESTINAL HAEMORRHAGIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM INTESTINAL
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM INTESTINAL HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL ULCER PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DYSPEPSIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DYSPHAGIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ENTERITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ENTEROCOLITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ENTEROVESICAL FISTULA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
FAECALOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC ULCER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC ULCER HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS EROSIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL HAEMORRHAGE
|
1.1%
14/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL EXFOLIATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL ULCER HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
TOOTH ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GINGIVAL BLEEDING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMATEMESIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMATOCHEZIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMORRHOIDAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMORRHOIDS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
HIATUS HERNIA
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ILEUS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
IMPAIRED GASTRIC EMPTYING
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INGUINAL HERNIA
|
1.0%
13/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
INGUINAL HERNIA, OBSTRUCTIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL ISCHAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
LARGE INTESTINE PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
LOWER GASTROINTESTINAL HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MALLORY-WEISS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MELAENA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MESENTERIC HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
NAUSEA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
OBSTRUCTION GASTRIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGEAL STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATIC MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS
|
0.08%
1/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
PROCTALGIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
PROCTITIS ULCERATIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
RECTAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Gastrointestinal disorders
RECTAL POLYP
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
RETROPERITONEAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Gastrointestinal disorders
SPIGELIAN HERNIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
STOMATITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
UMBILICAL HERNIA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
UPPER GASTROINTESTINAL HAEMORRHAGE
|
0.54%
7/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
VOLVULUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
VOMITING
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
ADVERSE DRUG REACTION
|
0.23%
3/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
General disorders
ASTHENIA
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
General disorders
CARDIAC COMPLICATION ASSOCIATED WITH DEVICE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CARDIAC DEATH
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CATHETER SITE HAEMATOMA
|
0.31%
4/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
CATHETER SITE NECROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
CHEST DISCOMFORT
|
0.62%
8/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
General disorders
CHEST PAIN
|
2.8%
36/1296 • 5 years
|
2.2%
29/1308 • 5 years
|
|
General disorders
CHILLS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
COMPLICATION OF DEVICE REMOVAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
DEATH
|
0.54%
7/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
General disorders
DEVICE BREAKAGE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE ISSUE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE MALFUNCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
DEVICE MATERIAL ISSUE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DISEASE PROGRESSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
EARLY SATIETY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
FACIAL PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
FATIGUE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
GAIT DISTURBANCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
GENERAL PHYSICAL HEALTH DETERIORATION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
HERNIA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
HYPERTHERMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
IMPAIRED HEALING
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
MALAISE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE COMPLICATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE SITE REACTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
METAPLASIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MULTI-ORGAN FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
NON-CARDIAC CHEST PAIN
|
5.9%
76/1296 • 5 years
|
6.3%
83/1308 • 5 years
|
|
General disorders
OEDEMA PERIPHERAL
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
PAIN
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
PYREXIA
|
0.46%
6/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
STENT-GRAFT ENDOLEAK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SUDDEN CARDIAC DEATH
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
THROMBOSIS IN DEVICE
|
0.93%
12/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
General disorders
ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
ACUTE HEPATIC FAILURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
BILE DUCT OBSTRUCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
BILE DUCT STONE
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Hepatobiliary disorders
BILIARY COLIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
BILIARY DYSKINESIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLANGITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLANGITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLELITHIASIS
|
0.69%
9/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Hepatobiliary disorders
CIRRHOSIS ALCOHOLIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
GALLBLADDER DISORDER
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC CIRRHOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC STEATOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATORENAL FAILURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
ISCHAEMIC HEPATITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
JAUNDICE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
JAUNDICE CHOLESTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
NON-ALCOHOLIC STEATOHEPATITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
ALLERGY TO ARTHROPOD STING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
AMYLOIDOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
ANAPHYLACTIC REACTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Immune system disorders
DRUG HYPERSENSITIVITY
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABDOMINAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
ABDOMINAL SEPSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS LIMB
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ABSCESS NECK
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS OF SALIVARY GLAND
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS ORAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
APPENDICITIS
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
ARTERIOVENOUS GRAFT SITE INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ARTHRITIS INFECTIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BACTERIAL SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BRONCHIOLITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BRONCHITIS
|
0.46%
6/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
BRONCHITIS VIRAL
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
BRONCHOPNEUMONIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BURSITIS INFECTIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CELLULITIS
|
0.62%
8/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Infections and infestations
CELLULITIS OF MALE EXTERNAL GENITAL ORGAN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
CHOLECYSTITIS INFECTIVE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIUM COLITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE COLITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
CORONA VIRUS INFECTION
|
0.54%
7/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CYSTITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
DEVICE RELATED INFECTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
DIABETIC FOOT INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
DIVERTICULITIS
|
0.69%
9/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
Infections and infestations
EAR INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
EMPYEMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ENDOCARDITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ENTEROCOCCAL BACTERAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ENTEROCOLITIS INFECTIOUS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
EXTRADURAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GANGRENE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GASTRIC INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GASTROENTERITIS
|
0.46%
6/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Infections and infestations
GASTROENTERITIS VIRAL
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
HEPATITIS C
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
HERPES ZOSTER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
HERPES ZOSTER OTICUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
IMPLANT SITE INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
INCISION SITE INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFECTED DERMAL CYST
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFECTED SKIN ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
INFECTIOUS PLEURAL EFFUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFLUENZA
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
KLEBSIELLA BACTERAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
KLEBSIELLA SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LABYRINTHITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LIVER ABSCESS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LOBAR PNEUMONIA
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LUNG INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LUNG INFECTION PSEUDOMONAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
MUSCLE ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
NECROTISING FASCIITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
OSTEOMYELITIS
|
0.00%
0/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
OSTEOMYELITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PERIUMBILICAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PHARYNGEAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PHARYNGITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PLEURAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA
|
2.9%
37/1296 • 5 years
|
2.6%
34/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA KLEBSIELLA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA STREPTOCOCCAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA VIRAL
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
POST PROCEDURAL CELLULITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
POSTOPERATIVE ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
POSTOPERATIVE WOUND INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PYELONEPHRITIS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
PYELONEPHRITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
RHINOVIRUS INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SCROTAL ABSCESS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SEPSIS
|
1.5%
19/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Infections and infestations
SEPSIS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SEPTIC ENCEPHALOPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SEPTIC SHOCK
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL SEPSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SUBCUTANEOUS ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
TESTICULAR ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
TOOTH INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
URETHRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.77%
10/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Infections and infestations
UROSEPSIS
|
0.39%
5/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
VIRAL INFECTION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
VIRAL LABYRINTHITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
WEST NILE VIRAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
WOUND INFECTION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
WOUND INFECTION BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ACETABULUM FRACTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ADRENAL GLAND INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ALCOHOL POISONING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANAEMIA POSTOPERATIVE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANASTOMOTIC LEAK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANASTOMOTIC ULCER HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANKLE FRACTURE
|
0.15%
2/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ARTERIAL INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ARTHROPOD STING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ASBESTOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
BACK INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CARDIAC PROCEDURE COMPLICATION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CATHETER SITE HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CERVICAL VERTEBRAL FRACTURE
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
COMMINUTED FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONCUSSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONFUSION POSTOPERATIVE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONTUSION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CORONARY ARTERY REOCCLUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CORONARY ARTERY RESTENOSIS
|
2.2%
28/1296 • 5 years
|
1.5%
20/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CRANIOCEREBRAL INJURY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CYSTITIS RADIATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FACIAL BONES FRACTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FALL
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FEMORAL NECK FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FEMUR FRACTURE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FIBULA FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FOOT FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FOREARM FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FRACTURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
GASTROINTESTINAL STOMA COMPLICATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HAEMATURIA TRAUMATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HAND FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HEAT EXHAUSTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HEAT STROKE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HIP FRACTURE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HUMERUS FRACTURE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
IN-STENT ARTERIAL RESTENOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
IN-STENT CORONARY ARTERY RESTENOSIS
|
0.62%
8/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INCISIONAL HERNIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INJURY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INTENTIONAL OVERDOSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
JOINT DISLOCATION
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LACERATION
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LIMB INJURY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LUMBAR VERTEBRAL FRACTURE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MENISCUS LESION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MULTIPLE FRACTURES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MULTIPLE INJURIES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
OVERDOSE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PATELLA FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PELVIC FRACTURE
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PELVIC ORGAN INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PERIPROSTHETIC FRACTURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PLAQUE SHIFT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POISONING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POISONING DELIBERATE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST LAMINECTOMY SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL BILE LEAK
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL COMPLICATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL MYOCARDIAL INFARCTION
|
0.85%
11/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST-TRAUMATIC PAIN
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE ILEUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE RESPIRATORY DISTRESS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL HYPERTENSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL PAIN
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL VOMITING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
RADIUS FRACTURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
RIB FRACTURE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ROAD TRAFFIC ACCIDENT
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SKULL FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL COLUMN INJURY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
|
0.31%
4/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL FRACTURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
STAB WOUND
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
STRESS ECHOCARDIOGRAM ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUBDURAL HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUBDURAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TENDON RUPTURE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
THERMAL BURN
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
THORACIC VERTEBRAL FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC ARTHRITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC HAEMATOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC INTRACRANIAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC LUNG INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ULNA FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
UPPER LIMB FRACTURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
URINARY RETENTION POSTOPERATIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR GRAFT COMPLICATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR GRAFT OCCLUSION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR PSEUDOANEURYSM
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WOUND DEHISCENCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WRIST FRACTURE
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
ARTERIOGRAM CORONARY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE MB INCREASED
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD GLUCOSE DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD GLUCOSE INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD PRESSURE INCREASED
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
CARDIAC ENZYMES INCREASED
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Investigations
CARDIAC STRESS TEST ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
ELECTROCARDIOGRAM ABNORMAL
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
GLYCOSYLATED HAEMOGLOBIN INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
TRANSAMINASES INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
TROPONIN INCREASED
|
0.46%
6/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
|
0.31%
4/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETIC KETOACIDOSIS
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Metabolism and nutrition disorders
FAILURE TO THRIVE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
FLUID OVERLOAD
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
GOUT
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERAMMONAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERCALCAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERGLYCAEMIA
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERKALAEMIA
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOGLYCAEMIA
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPONATRAEMIA
|
0.00%
0/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOVOLAEMIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
KETOACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
LACTIC ACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
MALNUTRITION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
METABOLIC ACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
METABOLIC SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
OBESITY
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
TYPE 2 DIABETES MELLITUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
0.54%
7/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHRITIS
|
0.46%
6/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
0.77%
10/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
BURSITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CERVICAL SPINAL STENOSIS
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CHONDROCALCINOSIS PYROPHOSPHATE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
COSTOCHONDRITIS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FACET JOINT SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FEMOROACETABULAR IMPINGEMENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FOOT DEFORMITY
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC DEGENERATION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
JOINT SWELLING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
LUMBAR SPINAL STENOSIS
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE NECROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULAR WEAKNESS
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL DISCOMFORT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL PAIN
|
0.31%
4/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MYALGIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MYOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
NECK PAIN
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
|
2.2%
29/1296 • 5 years
|
1.8%
24/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOCHONDROSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEONECROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOPOROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
POLYMYALGIA RHEUMATICA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PSEUDARTHROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
RHABDOMYOLYSIS
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
RHEUMATOID ARTHRITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ROTATOR CUFF SYNDROME
|
0.46%
6/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL COLUMN STENOSIS
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL OSTEOARTHRITIS
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TENDONITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TENOSYNOVITIS STENOSANS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TRIGGER FINGER
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
VERTEBRAL FORAMINAL STENOSIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE MYELOID LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE PROMYELOCYTIC LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA PANCREAS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE I
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE IV
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BASAL CELL CARCINOMA
|
0.23%
3/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN NEOPLASM OF BLADDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN SOFT TISSUE NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BILE DUCT CANCER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER CANCER
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BOWEN'S DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER IN SITU
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER STAGE II
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BRONCHIAL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CHRONIC LYMPHOCYTIC LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON ADENOMA
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
|
0.46%
6/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER METASTATIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GASTROINTESTINAL STROMAL TUMOUR
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT RECURRENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
INTESTINAL ADENOCARCINOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LARYNGEAL CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CANCER METASTATIC
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LYMPHOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT GLIOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA IN SITU
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT PLEURAL EFFUSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MANTLE CELL LYMPHOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MELANOCYTIC NAEVUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO CENTRAL NERVOUS SYSTEM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO LIVER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC MALIGNANT MELANOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MUELLER'S MIXED TUMOUR
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MULTIPLE MYELOMA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELODYSPLASTIC SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELOFIBROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM MALIGNANT
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM SKIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEUROENDOCRINE CARCINOMA METASTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-HODGKIN'S LYMPHOMA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OESOPHAGEAL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OROPHARYNGEAL CANCER STAGE UNSPECIFIED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER METASTATIC
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER STAGE III
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PARATHYROID TUMOUR BENIGN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PERITONEAL CARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLASMACYTOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA MALIGNANT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER
|
0.62%
8/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER METASTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL ADENOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL CANCER
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CANCER
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CELL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND CANCER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SEBORRHOEIC KERATOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN CANCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRACHEAL CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRANSITIONAL CELL CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
URETERIC CANCER RECURRENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
AMNESIA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
APHASIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
BRAIN INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
BRAIN MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
BRAIN STEM INFARCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERY OCCLUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERY STENOSIS
|
0.85%
11/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Nervous system disorders
CARPAL TUNNEL SYNDROME
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
CENTRAL NERVOUS SYSTEM LESION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CEREBELLAR INFARCTION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
CEREBRAL HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
CEREBRAL INFARCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CEREBROVASCULAR ACCIDENT
|
1.2%
15/1296 • 5 years
|
1.6%
21/1308 • 5 years
|
|
Nervous system disorders
CEREBROVASCULAR DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CERVICAL CORD COMPRESSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CERVICAL MYELOPATHY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CERVICOBRACHIAL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
COMPLICATED MIGRAINE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CONVULSION
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
CRANIAL NERVE DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CUBITAL TUNNEL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DEMENTIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DEMENTIA ALZHEIMER'S TYPE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DEPRESSED LEVEL OF CONSCIOUSNESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
DIZZINESS
|
0.31%
4/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Nervous system disorders
DYSARTHRIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
EMBOLIC CEREBRAL INFARCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ENCEPHALOPATHY
|
0.39%
5/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
EPILEPSY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
GRAND MAL CONVULSION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
GUILLAIN-BARRE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
HAEMORRHAGE INTRACRANIAL
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
HAEMORRHAGIC STROKE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
HEADACHE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
HYPOAESTHESIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
IIIRD NERVE PARALYSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
INTRACRANIAL ANEURYSM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
INTRAVENTRICULAR HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ISCHAEMIC STROKE
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
LUMBAR RADICULOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
METABOLIC ENCEPHALOPATHY
|
0.46%
6/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
MIGRAINE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
MIGRAINE WITH AURA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
MONONEURITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
MULTIPLE SCLEROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
NEURODEGENERATIVE DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
PARKINSON'S DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
PARTIAL SEIZURES
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
PRESYNCOPE
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Nervous system disorders
RADICULOPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
SCIATICA
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
SENSORY LOSS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
SUBARACHNOID HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Nervous system disorders
SYNCOPE
|
1.2%
15/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Nervous system disorders
TOXIC ENCEPHALOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
|
1.1%
14/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Nervous system disorders
TREMOR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TRIGEMINAL NEURALGIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TYPICAL AURA WITHOUT HEADACHE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ULNAR TUNNEL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
UNRESPONSIVE TO STIMULI
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
VERTEBRAL ARTERY STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
VIITH NERVE PARALYSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Pregnancy, puerperium and perinatal conditions
ABORTION SPONTANEOUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
ALCOHOL WITHDRAWAL SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
ANXIETY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
COMPLETED SUICIDE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
CONFUSIONAL STATE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
CONVERSION DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
DELIRIUM
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
DEPRESSION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
DEPRESSION SUICIDAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
IMPAIRED SELF-CARE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
INTENTIONAL SELF-INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
MENTAL STATUS CHANGES
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Psychiatric disorders
POST-TRAUMATIC AMNESTIC DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
PSYCHOGENIC PAIN DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
SOMATOFORM DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
SUICIDAL IDEATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
SUICIDE ATTEMPT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER NECK OBSTRUCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER OBSTRUCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
CALCULUS BLADDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
CALCULUS URETERIC
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Renal and urinary disorders
CYSTITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
DYSURIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
HAEMATURIA
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Renal and urinary disorders
HYDRONEPHROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
HYPERTONIC BLADDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
NEPHROLITHIASIS
|
0.54%
7/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Renal and urinary disorders
OBSTRUCTIVE UROPATHY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Renal and urinary disorders
RENAL ARTERY STENOSIS
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
RENAL FAILURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
RENAL FAILURE CHRONIC
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Renal and urinary disorders
RENAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
RENAL IMPAIRMENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
RENAL MASS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URETERIC STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URINARY INCONTINENCE
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
ACQUIRED HYDROCELE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
|
0.39%
5/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Reproductive system and breast disorders
ENDOMETRIAL HYPERPLASIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
EPIDIDYMITIS
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Reproductive system and breast disorders
ERECTILE DYSFUNCTION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
GENITAL PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
GYNAECOMASTIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
MENORRHAGIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
PELVIC PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
PROSTATITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
PROSTATOMEGALY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
UTERINE OBSTRUCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
UTERINE POLYP
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
VAGINAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
VAGINAL PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
VULVAR DYSPLASIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACQUIRED DIAPHRAGMATIC EVENTRATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE INTERSTITIAL PNEUMONITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY OEDEMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY DISTRESS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY FAILURE
|
1.2%
15/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ASPIRATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ASTHMA
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ATELECTASIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
1.2%
16/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC RESPIRATORY FAILURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DIAPHRAGMATIC PARALYSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
1.6%
21/1296 • 5 years
|
1.8%
24/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
|
0.69%
9/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
EMPHYSEMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HAEMOPTYSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HAEMOTHORAX
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HYPOXIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
LUNG INFILTRATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
NASAL SEPTUM DEVIATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
NASAL TURBINATE HYPERTROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL FIBROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMONIA ASPIRATION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMONITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.62%
8/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY FIBROSIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY HYPERTENSION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY MASS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY OEDEMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY TOXICITY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ARREST
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY DISTRESS
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
|
0.93%
12/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
SLEEP APNOEA SYNDROME
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ANGIOEDEMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DECUBITUS ULCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DIGITAL ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DRUG ERUPTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DRY GANGRENE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
LEUKOCYTOCLASTIC VASCULITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PRECANCEROUS SKIN LESION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
RASH
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SCAR PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SKIN ULCER
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Surgical and medical procedures
AORTIC STENT INSERTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
CORONARY ARTERIAL STENT INSERTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
HERNIA REPAIR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
HIP ARTHROPLASTY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
HYSTERECTOMY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
IMPLANTABLE DEFIBRILLATOR INSERTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
KNEE ARTHROPLASTY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
NASAL OPERATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
NECK SURGERY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
PERCUTANEOUS CORONARY INTERVENTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
ROTATOR CUFF REPAIR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
SURGERY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ACCELERATED HYPERTENSION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ANEURYSM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
AORTIC ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Vascular disorders
AORTIC DISSECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
AORTIC STENOSIS
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Vascular disorders
ARTERIAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ARTERIAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIAL OCCLUSIVE DISEASE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ARTERIAL THROMBOSIS LIMB
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIOSCLEROSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
DEEP VEIN THROMBOSIS
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Vascular disorders
EMBOLISM ARTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERIAL STENOSIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY DISSECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY OCCLUSION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
HYPERTENSION
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Vascular disorders
HYPERTENSIVE CRISIS
|
0.39%
5/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Vascular disorders
HYPERTENSIVE EMERGENCY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
HYPOTENSION
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Vascular disorders
HYPOVOLAEMIC SHOCK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ILIAC ARTERY STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
INTERMITTENT CLAUDICATION
|
0.62%
8/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Vascular disorders
LERICHE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
MALIGNANT HYPERTENSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ORTHOSTATIC HYPOTENSION
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Vascular disorders
PELVIC VENOUS THROMBOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
|
0.54%
7/1296 • 5 years
|
1.1%
15/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL ISCHAEMIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL VASCULAR DISORDER
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Vascular disorders
SHOCK
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
THROMBOPHLEBITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
THROMBOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VARICOSE VEIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VASCULAR STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
VENOUS RECANALISATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VENOUS THROMBOSIS LIMB
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
Other adverse events
| Measure |
Absorb BVS
n=1296 participants at risk
Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
|
XIENCE
n=1308 participants at risk
Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
|
|---|---|---|
|
Nervous system disorders
HYPOAESTHESIA
|
2.1%
27/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Nervous system disorders
IIIRD NERVE PARALYSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
PHIMOSIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Congenital, familial and genetic disorders
URACHAL ABNORMALITY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL ISCHAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
CERUMEN IMPACTION
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
OTITIS MEDIA CHRONIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PELVIC INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PERIUMBILICAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PHARYNGEAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PHARYNGITIS
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
PHARYNGITIS BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PHARYNGITIS STREPTOCOCCAL
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
PLEURAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
HEART RATE DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOARTHRITIS
|
2.7%
35/1296 • 5 years
|
2.4%
31/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOCHONDROSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEONECROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOPOROSIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
OSTEOSCLEROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
|
1.7%
22/1296 • 5 years
|
2.8%
36/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PAIN IN JAW
|
0.39%
5/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PERIARTHRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PLANTAR FASCIAL FIBROMATOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PLANTAR FASCIITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
POLYMYALGIA RHEUMATICA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PSEUDARTHROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
PSORIATIC ARTHROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
RHABDOMYOLYSIS
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
GASTROINTESTINAL ARTERIOVENOUS MALFORMATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Congenital, familial and genetic disorders
HYDROCELE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
ANAEMIA
|
1.8%
23/1296 • 5 years
|
2.2%
29/1308 • 5 years
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Blood and lymphatic system disorders
HAEMORRHAGIC ANAEMIA
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Blood and lymphatic system disorders
HAEMORRHAGIC DIATHESIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Blood and lymphatic system disorders
IRON DEFICIENCY ANAEMIA
|
0.54%
7/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
Blood and lymphatic system disorders
LEUKOCYTOSIS
|
0.00%
0/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Blood and lymphatic system disorders
LYMPHADENOPATHY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
NORMOCHROMIC NORMOCYTIC ANAEMIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Blood and lymphatic system disorders
PANCYTOPENIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
SPLENIC GRANULOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ACCELERATED IDIOVENTRICULAR RHYTHM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ACUTE CORONARY SYNDROME
|
0.77%
10/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Cardiac disorders
ACUTE LEFT VENTRICULAR FAILURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ACUTE MYOCARDIAL INFARCTION
|
2.2%
28/1296 • 5 years
|
2.1%
28/1308 • 5 years
|
|
Cardiac disorders
ANGINA PECTORIS
|
26.4%
342/1296 • 5 years
|
25.4%
332/1308 • 5 years
|
|
Cardiac disorders
ANGINA UNSTABLE
|
4.7%
61/1296 • 5 years
|
5.4%
70/1308 • 5 years
|
|
Cardiac disorders
AORTIC VALVE INCOMPETENCE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
AORTIC VALVE STENOSIS
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
ARRHYTHMIA
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
ARTERIOSCLEROSIS CORONARY ARTERY
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
ARTERIOSPASM CORONARY
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
6.0%
78/1296 • 5 years
|
4.4%
57/1308 • 5 years
|
|
Cardiac disorders
ATRIAL FLUTTER
|
0.31%
4/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Cardiac disorders
ATRIAL TACHYCARDIA
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ATRIAL THROMBOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK COMPLETE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK SECOND DEGREE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
BRADYCARDIA
|
1.6%
21/1296 • 5 years
|
1.2%
16/1308 • 5 years
|
|
Cardiac disorders
BUNDLE BRANCH BLOCK LEFT
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
BUNDLE BRANCH BLOCK RIGHT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIAC ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIAC ARREST
|
0.77%
10/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE
|
1.2%
16/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE ACUTE
|
0.46%
6/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE CHRONIC
|
0.39%
5/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FAILURE CONGESTIVE
|
2.5%
33/1296 • 5 years
|
2.2%
29/1308 • 5 years
|
|
Cardiac disorders
CARDIAC FLUTTER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIAC PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIAC TAMPONADE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIAC VALVE DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIO-RESPIRATORY ARREST
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
CARDIOGENIC SHOCK
|
0.39%
5/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CARDIOMYOPATHY
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
CARDIOPULMONARY FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CARDIOVASCULAR DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CHRONOTROPIC INCOMPETENCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CONGESTIVE CARDIOMYOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
COR PULMONALE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY DISEASE
|
3.8%
49/1296 • 5 years
|
3.6%
47/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY DISSECTION
|
7.1%
92/1296 • 5 years
|
4.8%
63/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY EMBOLISM
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY OCCLUSION
|
0.62%
8/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY PERFORATION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY STENOSIS
|
1.2%
16/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Cardiac disorders
CORONARY ARTERY THROMBOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
CYANOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
DIASTOLIC DYSFUNCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
EXTRASYSTOLES
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
HEART VALVE INCOMPETENCE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
HYPERTENSIVE HEART DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
HYPERTROPHIC CARDIOMYOPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
IN-STENT CORONARY ARTERY RESTENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
INTRACARDIAC THROMBUS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
INTRAPERICARDIAL THROMBOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
ISCHAEMIC CARDIOMYOPATHY
|
0.39%
5/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
Cardiac disorders
LEFT VENTRICULAR DYSFUNCTION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
LEFT VENTRICULAR HYPERTROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
MICROVASCULAR ANGINA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE INCOMPETENCE
|
0.54%
7/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE PROLAPSE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
MITRAL VALVE STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
MYOCARDIAL INFARCTION
|
5.8%
75/1296 • 5 years
|
4.5%
59/1308 • 5 years
|
|
Cardiac disorders
MYOCARDIAL ISCHAEMIA
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Cardiac disorders
MYOCARDITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
MYOPERICARDITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
NODAL ARRHYTHMIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
PALPITATIONS
|
2.2%
28/1296 • 5 years
|
2.6%
34/1308 • 5 years
|
|
Cardiac disorders
PERICARDIAL EFFUSION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
PERICARDIAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
PERICARDITIS
|
0.31%
4/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Cardiac disorders
PRINZMETAL ANGINA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
PULSELESS ELECTRICAL ACTIVITY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
RESTRICTIVE CARDIOMYOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
SICK SINUS SYNDROME
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
SINUS ARREST
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
SINUS BRADYCARDIA
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Cardiac disorders
SINUS TACHYCARDIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
STRESS CARDIOMYOPATHY
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
SUPRAVENTRICULAR EXTRASYSTOLES
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
SUPRAVENTRICULAR TACHYCARDIA
|
0.39%
5/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Cardiac disorders
TACHYARRHYTHMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
PERONEAL MUSCULAR ATROPHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
TACHYCARDIA
|
0.62%
8/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Cardiac disorders
TRICUSPID VALVE INCOMPETENCE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR ARRHYTHMIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR EXTRASYSTOLES
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR FIBRILLATION
|
0.46%
6/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Cardiac disorders
VENTRICULAR TACHYCARDIA
|
1.1%
14/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Congenital, familial and genetic disorders
ARTERIOVENOUS MALFORMATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Congenital, familial and genetic disorders
ATRIAL SEPTAL DEFECT
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Congenital, familial and genetic disorders
CORNEAL DYSTROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Ear and labyrinth disorders
DEAFNESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Ear and labyrinth disorders
DEAFNESS UNILATERAL
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
EAR CONGESTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Ear and labyrinth disorders
EAR HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
EAR PAIN
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
EUSTACHIAN TUBE DYSFUNCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
NEUROSENSORY HYPOACUSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Ear and labyrinth disorders
TINNITUS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Ear and labyrinth disorders
TYMPANIC MEMBRANE PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Ear and labyrinth disorders
VERTIGO
|
0.62%
8/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Ear and labyrinth disorders
VERTIGO POSITIONAL
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Endocrine disorders
ADRENAL INSUFFICIENCY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Endocrine disorders
ADRENAL MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
CARCINOID SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
GOITRE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPERPARATHYROIDISM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPERTHYROIDISM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPOGONADISM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Endocrine disorders
HYPOTHYROIDIC GOITRE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Endocrine disorders
HYPOTHYROIDISM
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Endocrine disorders
SECONDARY HYPOGONADISM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Endocrine disorders
THYROID MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
ABNORMAL SENSATION IN EYE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
AGE-RELATED MACULAR DEGENERATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
AMAUROSIS FUGAX
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Eye disorders
BLINDNESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
BLINDNESS TRANSIENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
CATARACT
|
0.77%
10/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Eye disorders
CONJUNCTIVAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Eye disorders
CONJUNCTIVITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
DIABETIC RETINOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
DIPLOPIA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Eye disorders
DRY EYE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
EYE HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Eye disorders
EYE PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Eye disorders
GLAUCOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
LACRIMAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Eye disorders
MACULAR DEGENERATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
MACULAR FIBROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
MACULAR OEDEMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
OCULAR HYPERAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL ARTERY EMBOLISM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL DETACHMENT
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Eye disorders
RETINAL DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINAL TEAR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
RETINOPATHY PROLIFERATIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
TOLOSA-HUNT SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
VISION BLURRED
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Eye disorders
VISUAL IMPAIRMENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Eye disorders
VITREOUS DETACHMENT
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Eye disorders
VITREOUS HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL DISCOMFORT
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL DISTENSION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL HERNIA
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
1.2%
15/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN LOWER
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
1.2%
16/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Gastrointestinal disorders
ANAL FISSURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ANAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
APPENDIX DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ASCITES
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
BARRETT'S OESOPHAGUS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
BOWEL MOVEMENT IRREGULARITY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
CHRONIC GASTROINTESTINAL BLEEDING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS
|
0.54%
7/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS ISCHAEMIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
COLITIS ULCERATIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
COLONIC POLYP
|
0.39%
5/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Gastrointestinal disorders
CONSTIPATION
|
0.46%
6/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Gastrointestinal disorders
CROHN'S DISEASE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DENTAL CARIES
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DIARRHOEA
|
1.4%
18/1296 • 5 years
|
1.5%
20/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULAR PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULITIS INTESTINAL HAEMORRHAGIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM INTESTINAL
|
0.15%
2/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Gastrointestinal disorders
DIVERTICULUM INTESTINAL HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENAL ULCER PERFORATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
DUODENITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
DYSPEPSIA
|
0.85%
11/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Gastrointestinal disorders
DYSPHAGIA
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
ENTERITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ENTEROCOLITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ENTEROVESICAL FISTULA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
EPIGASTRIC DISCOMFORT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
EROSIVE OESOPHAGITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ERUCTATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
FAECALOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
FAECES DISCOLOURED
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
FLATULENCE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
FOOD POISONING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC DISORDER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC POLYPS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC ULCER
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRIC ULCER HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS
|
0.54%
7/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS EROSIVE
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
GASTRITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL HAEMORRHAGE
|
1.3%
17/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL MOTILITY DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL MUCOSAL EXFOLIATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROINTESTINAL ULCER HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
|
1.5%
19/1296 • 5 years
|
1.2%
16/1308 • 5 years
|
|
Gastrointestinal disorders
GINGIVAL BLEEDING
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
GINGIVAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMATEMESIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMATOCHEZIA
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMORRHOIDAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
HAEMORRHOIDS
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
HIATUS HERNIA
|
0.39%
5/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Gastrointestinal disorders
ILEUS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
IMPAIRED GASTRIC EMPTYING
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
INGUINAL HERNIA
|
1.1%
14/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Gastrointestinal disorders
INGUINAL HERNIA, OBSTRUCTIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
INTESTINAL MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
IRRITABLE BOWEL SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
LARGE INTESTINE PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
LIP HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
LIP SWELLING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
LOWER GASTROINTESTINAL HAEMORRHAGE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MALLORY-WEISS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MELAENA
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Gastrointestinal disorders
MELANOSIS COLI
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MESENTERIC HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
MOUTH HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
MOUTH ULCERATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
NAUSEA
|
2.6%
34/1296 • 5 years
|
2.7%
35/1308 • 5 years
|
|
Gastrointestinal disorders
OBSTRUCTION GASTRIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
ODYNOPHAGIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGEAL HYPOMOTILITY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGEAL SPASM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGEAL STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
OESOPHAGITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
ORAL MUCOSAL DISCOLOURATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATIC MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS
|
0.08%
1/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Gastrointestinal disorders
PANCREATITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
PARAESTHESIA ORAL
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
POLYP COLORECTAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
PROCTALGIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
PROCTITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
PROCTITIS ULCERATIVE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
RECTAL HAEMORRHAGE
|
0.62%
8/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Gastrointestinal disorders
RECTAL POLYP
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
RETROPERITONEAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
SALIVARY GLAND MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Gastrointestinal disorders
SPIGELIAN HERNIA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
STOMACH MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
STOMATITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Gastrointestinal disorders
SWOLLEN TONGUE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
TOOTH DISORDER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
TOOTH LOSS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
TOOTHACHE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
UMBILICAL HERNIA
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Gastrointestinal disorders
UPPER GASTROINTESTINAL HAEMORRHAGE
|
0.54%
7/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Gastrointestinal disorders
VOLVULUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Gastrointestinal disorders
VOMITING
|
0.39%
5/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
General disorders
ADVERSE DRUG REACTION
|
6.0%
78/1296 • 5 years
|
5.7%
75/1308 • 5 years
|
|
General disorders
ASTHENIA
|
2.1%
27/1296 • 5 years
|
1.6%
21/1308 • 5 years
|
|
General disorders
AXILLARY PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
CARDIAC COMPLICATION ASSOCIATED WITH DEVICE
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CARDIAC DEATH
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CATHETER SITE HAEMATOMA
|
2.0%
26/1296 • 5 years
|
2.4%
32/1308 • 5 years
|
|
General disorders
CATHETER SITE HAEMORRHAGE
|
0.62%
8/1296 • 5 years
|
1.2%
16/1308 • 5 years
|
|
General disorders
CATHETER SITE NECROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
CATHETER SITE PAIN
|
0.69%
9/1296 • 5 years
|
1.6%
21/1308 • 5 years
|
|
General disorders
CATHETER SITE RASH
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CATHETER SITE RELATED REACTION
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
General disorders
CATHETER SITE SWELLING
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
CHEST DISCOMFORT
|
4.6%
60/1296 • 5 years
|
5.0%
65/1308 • 5 years
|
|
General disorders
CHEST PAIN
|
8.1%
105/1296 • 5 years
|
8.4%
110/1308 • 5 years
|
|
General disorders
CHILLS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
COMPLICATION OF DEVICE REMOVAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
CYST
|
0.00%
0/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
General disorders
DEATH
|
0.54%
7/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
General disorders
DEVICE BREAKAGE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE FAILURE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
DEVICE ISSUE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE MALFUNCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
DEVICE MATERIAL ISSUE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DEVICE OCCLUSION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DISEASE PROGRESSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
DRUG INTOLERANCE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
EARLY SATIETY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
EXERCISE TOLERANCE DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
FACIAL PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
FATIGUE
|
3.5%
45/1296 • 5 years
|
3.3%
43/1308 • 5 years
|
|
General disorders
FEELING COLD
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
FEELING HOT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
GAIT DISTURBANCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
GENERAL PHYSICAL HEALTH DETERIORATION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
GENERALISED OEDEMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
GRANULOMA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
HERNIA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
HYPERTHERMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
IMPAIRED HEALING
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
INFLAMMATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
INFLUENZA LIKE ILLNESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
INFUSION SITE PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
LOCAL SWELLING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MALAISE
|
0.69%
9/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE COMPLICATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
MEDICAL DEVICE SITE REACTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
METAPLASIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
MULTI-ORGAN FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
NON-CARDIAC CHEST PAIN
|
17.7%
230/1296 • 5 years
|
20.9%
274/1308 • 5 years
|
|
General disorders
OEDEMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
General disorders
OEDEMA PERIPHERAL
|
2.1%
27/1296 • 5 years
|
1.7%
22/1308 • 5 years
|
|
General disorders
PACEMAKER GENERATED ARRHYTHMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
PAIN
|
0.15%
2/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
General disorders
PATIENT-DEVICE INCOMPATIBILITY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
PYREXIA
|
0.69%
9/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
General disorders
SENSATION OF FOREIGN BODY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SPINAL PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
STENT-GRAFT ENDOLEAK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SUDDEN CARDIAC DEATH
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SWELLING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
General disorders
THROMBOSIS IN DEVICE
|
1.0%
13/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
General disorders
ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
General disorders
UNEVALUABLE EVENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
VESSEL PUNCTURE SITE HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
General disorders
VESSEL PUNCTURE SITE THROMBOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
ACUTE HEPATIC FAILURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
BILE DUCT OBSTRUCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
BILE DUCT STONE
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Hepatobiliary disorders
BILIARY COLIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
BILIARY DILATATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
BILIARY DYSKINESIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLANGITIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLANGITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLECYSTITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
CHOLELITHIASIS
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Hepatobiliary disorders
CIRRHOSIS ALCOHOLIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
GALLBLADDER DISORDER
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
GRANULOMATOUS LIVER DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC CIRRHOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC CYST
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC FAILURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC FUNCTION ABNORMAL
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC LESION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATIC STEATOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Hepatobiliary disorders
HEPATORENAL FAILURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
ISCHAEMIC HEPATITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
JAUNDICE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
JAUNDICE CHOLESTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Hepatobiliary disorders
NON-ALCOHOLIC STEATOHEPATITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
ALLERGY TO ARTHROPOD BITE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
ALLERGY TO ARTHROPOD STING
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
AMYLOIDOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
ANAPHYLACTIC REACTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Immune system disorders
CONTRAST MEDIA ALLERGY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
DRUG HYPERSENSITIVITY
|
0.46%
6/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Immune system disorders
FOOD ALLERGY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
HYPERSENSITIVITY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
SARCOIDOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Immune system disorders
SEASONAL ALLERGY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ABDOMINAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
ABDOMINAL SEPSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS LIMB
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
ABSCESS NECK
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS OF SALIVARY GLAND
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ABSCESS ORAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ACARODERMATITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ACUTE SINUSITIS
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
APPENDICITIS
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
ARTERIOVENOUS GRAFT SITE INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ARTHRITIS INFECTIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BACTERIAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BACTERIAL SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BODY TINEA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
BRONCHIOLITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BRONCHITIS
|
1.8%
23/1296 • 5 years
|
1.5%
20/1308 • 5 years
|
|
Infections and infestations
BRONCHITIS VIRAL
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
BRONCHOPNEUMONIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
BURSITIS INFECTIVE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CAMPYLOBACTER INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CATHETER SITE ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CATHETER SITE CELLULITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CELLULITIS
|
1.2%
15/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Infections and infestations
CELLULITIS OF MALE EXTERNAL GENITAL ORGAN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
CHOLECYSTITIS INFECTIVE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
CHRONIC SINUSITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIAL INFECTION
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIUM COLITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE COLITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
CONJUNCTIVITIS BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
CORONA VIRUS INFECTION
|
1.1%
14/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
CYSTITIS
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
DEVICE RELATED INFECTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
DIABETIC FOOT INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
DIVERTICULITIS
|
1.4%
18/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Infections and infestations
EAR INFECTION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
EMPYEMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ENDOCARDITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ENDOMETRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ENTEROCOCCAL BACTERAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ENTEROCOLITIS INFECTIOUS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
EPIDEMIC POLYARTHRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
EXTRADURAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
FURUNCLE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GANGRENE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GASTRIC INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
GASTRITIS VIRAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
GASTROENTERITIS
|
0.54%
7/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Infections and infestations
GASTROENTERITIS VIRAL
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
GASTROINTESTINAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
GENITAL HERPES
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
HELICOBACTER GASTRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
HELICOBACTER INFECTION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
HEPATITIS C
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
HERPES SIMPLEX
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
HERPES ZOSTER
|
0.46%
6/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Infections and infestations
HERPES ZOSTER OTICUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
IMPETIGO
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
IMPLANT SITE INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
INCISION SITE INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFECTED BITES
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFECTED CYST
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
INFECTED DERMAL CYST
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFECTED SKIN ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
INFECTIOUS PLEURAL EFFUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
INFLUENZA
|
1.0%
13/1296 • 5 years
|
1.5%
20/1308 • 5 years
|
|
Infections and infestations
INTERTRIGO CANDIDA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
KIDNEY INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
KLEBSIELLA BACTERAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
KLEBSIELLA SEPSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LABYRINTHITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LARYNGITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
LIVER ABSCESS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LOBAR PNEUMONIA
|
0.46%
6/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
LOCALISED INFECTION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
LUNG INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LUNG INFECTION PSEUDOMONAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LYME DISEASE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
LYMPH GLAND INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
MUSCLE ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
MYRINGITIS BULLOUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
NASOPHARYNGITIS
|
0.69%
9/1296 • 5 years
|
0.92%
12/1308 • 5 years
|
|
Infections and infestations
NECROTISING FASCIITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
OESOPHAGEAL CANDIDIASIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
ORAL CANDIDIASIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
ORAL FUNGAL INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
ORCHITIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
OSTEOMYELITIS
|
0.00%
0/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
OSTEOMYELITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
OTITIS EXTERNA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
OTITIS MEDIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
OTITIS MEDIA ACUTE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA
|
3.2%
42/1296 • 5 years
|
3.2%
42/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA ESCHERICHIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA KLEBSIELLA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA STREPTOCOCCAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
PNEUMONIA VIRAL
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
POST PROCEDURAL CELLULITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
POSTOPERATIVE ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
POSTOPERATIVE WOUND INFECTION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
PYELONEPHRITIS
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
PYELONEPHRITIS ACUTE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
RESPIRATORY TRACT INFECTION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
RESPIRATORY TRACT INFECTION VIRAL
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
RHINOVIRUS INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SCROTAL ABSCESS
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SEPSIS
|
1.5%
20/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Infections and infestations
SEPSIS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SEPTIC ENCEPHALOPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SEPTIC SHOCK
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Infections and infestations
SIALOADENITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SINOBRONCHITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SINUSITIS
|
0.85%
11/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Infections and infestations
SINUSITIS BACTERIAL
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
SKIN INFECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL ABSCESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL BACTERAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
STAPHYLOCOCCAL SEPSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
SUBCUTANEOUS ABSCESS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Infections and infestations
TESTICULAR ABSCESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
TINEA PEDIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
TOOTH ABSCESS
|
0.23%
3/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Infections and infestations
TOOTH INFECTION
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Infections and infestations
TRICHOMONIASIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
1.5%
20/1296 • 5 years
|
1.8%
24/1308 • 5 years
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION BACTERIAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
URETHRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
URINARY TRACT INFECTION
|
1.9%
24/1296 • 5 years
|
2.5%
33/1308 • 5 years
|
|
Infections and infestations
URINARY TRACT INFECTION BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
UROSEPSIS
|
0.39%
5/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
VAGINITIS BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
VESTIBULAR NEURONITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
VIRAL INFECTION
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
VIRAL LABYRINTHITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
VIRAL UPPER RESPIRATORY TRACT INFECTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Infections and infestations
WEST NILE VIRAL INFECTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
WOUND INFECTION
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Infections and infestations
WOUND INFECTION BACTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Infections and infestations
WOUND INFECTION STAPHYLOCOCCAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ACCIDENTAL OVERDOSE
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ACETABULUM FRACTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ADRENAL GLAND INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ALCOHOL POISONING
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANAEMIA POSTOPERATIVE
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANASTOMOTIC LEAK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANASTOMOTIC ULCER HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANIMAL BITE
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ANKLE FRACTURE
|
0.23%
3/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ARTERIAL INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ARTHROPOD BITE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ARTHROPOD STING
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ASBESTOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
AXILLARY NERVE INJURY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
BACK INJURY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CARDIAC PROCEDURE COMPLICATION
|
0.54%
7/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CATHETER SITE HAEMATOMA
|
0.23%
3/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CERVICAL VERTEBRAL FRACTURE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
COMMINUTED FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONCUSSION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONFUSION POSTOPERATIVE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONTRAST MEDIA ALLERGY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CONTUSION
|
1.2%
16/1296 • 5 years
|
1.7%
22/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CORNEAL ABRASION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CORONARY ARTERY REOCCLUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CORONARY ARTERY RESTENOSIS
|
2.3%
30/1296 • 5 years
|
1.6%
21/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CRANIOCEREBRAL INJURY
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
CYSTITIS RADIATION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
DEPRESSION POSTOPERATIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
DRUG ADMINISTRATION ERROR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
EAR INJURY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
EPICONDYLITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
EXCORIATION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
EXPOSURE TO TOXIC AGENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
EYE PENETRATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FACIAL BONES FRACTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FALL
|
1.3%
17/1296 • 5 years
|
1.6%
21/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FEMORAL NECK FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FEMUR FRACTURE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FIBULA FRACTURE
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FOOT FRACTURE
|
0.15%
2/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FOREARM FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FOREIGN BODY IN EYE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
FRACTURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
GASTROINTESTINAL DISORDER POSTOPERATIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
GASTROINTESTINAL STOMA COMPLICATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HAEMATURIA TRAUMATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HAND FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HEAD INJURY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HEAT EXHAUSTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HEAT STROKE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HIP FRACTURE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
HUMERUS FRACTURE
|
0.31%
4/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
IN-STENT ARTERIAL RESTENOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
IN-STENT CORONARY ARTERY RESTENOSIS
|
0.62%
8/1296 • 5 years
|
1.5%
19/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INCISION SITE PAIN
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INCISIONAL HERNIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INCORRECT DOSE ADMINISTERED
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INJURY
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
INTENTIONAL OVERDOSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
JOINT DISLOCATION
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
JOINT INJURY
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LACERATION
|
0.85%
11/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LIGAMENT SPRAIN
|
0.46%
6/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LIMB INJURY
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Injury, poisoning and procedural complications
LUMBAR VERTEBRAL FRACTURE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MENISCUS LESION
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MOUTH INJURY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MULTIPLE FRACTURES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MULTIPLE INJURIES
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MUSCLE RUPTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
MUSCLE STRAIN
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Injury, poisoning and procedural complications
OVERDOSE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PATELLA FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PELVIC FRACTURE
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PELVIC ORGAN INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PERIPROSTHETIC FRACTURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PLAQUE SHIFT
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POISONING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POISONING DELIBERATE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST LAMINECTOMY SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL BILE LEAK
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL COMPLICATION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL DISCOMFORT
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMATURIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL MYOCARDIAL INFARCTION
|
1.5%
20/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST PROCEDURAL OEDEMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POST-TRAUMATIC PAIN
|
0.62%
8/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE FEVER
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE HERNIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE ILEUS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
POSTOPERATIVE RESPIRATORY DISTRESS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL COMPLICATION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL DIZZINESS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL HEADACHE
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL HYPERTENSION
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL HYPOTENSION
|
0.77%
10/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL NAUSEA
|
0.62%
8/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL PAIN
|
1.2%
16/1296 • 5 years
|
1.1%
15/1308 • 5 years
|
|
Injury, poisoning and procedural complications
PROCEDURAL VOMITING
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
RADIUS FRACTURE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
RIB FRACTURE
|
0.54%
7/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ROAD TRAFFIC ACCIDENT
|
0.46%
6/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SEROMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SKELETAL INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SKULL FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL COLUMN INJURY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL COMPRESSION FRACTURE
|
0.39%
5/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SPINAL FRACTURE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
STAB WOUND
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUBCUTANEOUS HAEMATOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUBDURAL HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUBDURAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
SUTURE RUPTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TENDON RUPTURE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
THERMAL BURN
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
THORACIC VERTEBRAL FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TOOTH FRACTURE
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC ARTHRITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC INTRACRANIAL HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Injury, poisoning and procedural complications
TRAUMATIC LUNG INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
ULNA FRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
UPPER LIMB FRACTURE
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Injury, poisoning and procedural complications
URINARY RETENTION POSTOPERATIVE
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR GRAFT COMPLICATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR GRAFT OCCLUSION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Injury, poisoning and procedural complications
VASCULAR PSEUDOANEURYSM
|
0.54%
7/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WOUND COMPLICATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WOUND DEHISCENCE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WOUND HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Injury, poisoning and procedural complications
WRIST FRACTURE
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Investigations
ALANINE AMINOTRANSFERASE INCREASED
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
ANGIOGRAM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
ARTERIAL BRUIT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
ARTERIOGRAM CORONARY
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
ARTERIOGRAM CORONARY ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Investigations
BLOOD CHOLESTEROL DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD CHOLESTEROL INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE INCREASED
|
1.4%
18/1296 • 5 years
|
1.5%
20/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE MB ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE MB DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD CREATINE PHOSPHOKINASE MB INCREASED
|
5.2%
68/1296 • 5 years
|
4.5%
59/1308 • 5 years
|
|
Investigations
BLOOD CREATININE INCREASED
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD GLUCOSE DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD GLUCOSE INCREASED
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Investigations
BLOOD LACTIC ACID INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD MAGNESIUM DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
BLOOD POTASSIUM DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD PRESSURE DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
BLOOD PRESSURE INCREASED
|
0.93%
12/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Investigations
BLOOD PRESSURE SYSTOLIC DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD PRESSURE SYSTOLIC INCREASED
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
BLOOD TESTOSTERONE DECREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD TRIGLYCERIDES INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD URIC ACID INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BLOOD URINE PRESENT
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
BODY TEMPERATURE INCREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
CARDIAC ENZYMES INCREASED
|
11.5%
149/1296 • 5 years
|
11.5%
150/1308 • 5 years
|
|
Investigations
CARDIAC IMAGING PROCEDURE ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
CARDIAC MURMUR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
CARDIAC STRESS TEST ABNORMAL
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Investigations
CAROTID BRUIT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
CATHETERISATION CARDIAC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
COMPUTERISED TOMOGRAM THORAX ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
CORONAVIRUS TEST POSITIVE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
EJECTION FRACTION DECREASED
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
ELECTROCARDIOGRAM ABNORMAL
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
ELECTROCARDIOGRAM ST SEGMENT ELEVATION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
FEMORAL BRUIT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
FIBRIN D DIMER INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
GLYCOSYLATED HAEMOGLOBIN INCREASED
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
HAEMOGLOBIN DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
HEART RATE INCREASED
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Investigations
HEART RATE IRREGULAR
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Investigations
HEPATIC ENZYME INCREASED
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
INFLUENZA A VIRUS TEST POSITIVE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
LEFT VENTRICULAR END-DIASTOLIC PRESSURE INCREASED
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Investigations
LIVER FUNCTION TEST ABNORMAL
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
LIVER SCAN ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
LOW DENSITY LIPOPROTEIN INCREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
LYMPHOCYTE COUNT INCREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
MEAN CELL VOLUME ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
OCCULT BLOOD POSITIVE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
OESOPHAGOGASTRODUODENOSCOPY ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
OXYGEN SATURATION DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
PLATELET COUNT DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
POSITRON EMISSION TOMOGRAM ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
PROSTATIC SPECIFIC ANTIGEN INCREASED
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Investigations
SCAN MYOCARDIAL PERFUSION ABNORMAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
STRESS ECHOCARDIOGRAM ABNORMAL
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Investigations
TRANSAMINASES INCREASED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
TROPONIN I INCREASED
|
0.62%
8/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Investigations
TROPONIN INCREASED
|
8.4%
109/1296 • 5 years
|
6.6%
86/1308 • 5 years
|
|
Investigations
TROPONIN T INCREASED
|
1.1%
14/1296 • 5 years
|
0.92%
12/1308 • 5 years
|
|
Investigations
ULTRASOUND THYROID ABNORMAL
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Investigations
WEIGHT DECREASED
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Investigations
WEIGHT INCREASED
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Investigations
WHITE BLOOD CELL COUNT DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
CARBOHYDRATE INTOLERANCE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
0.62%
8/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS
|
0.62%
8/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
|
0.39%
5/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Metabolism and nutrition disorders
DIABETIC KETOACIDOSIS
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Metabolism and nutrition disorders
FAILURE TO THRIVE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
FLUID OVERLOAD
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
GLUCOSE TOLERANCE IMPAIRED
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
GOUT
|
0.77%
10/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERAMMONAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERCALCAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERCHOLESTEROLAEMIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERGLYCAEMIA
|
0.54%
7/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERKALAEMIA
|
0.39%
5/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERLIPIDAEMIA
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERTRIGLYCERIDAEMIA
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPERURICAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOGLYCAEMIA
|
0.54%
7/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPONATRAEMIA
|
0.00%
0/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOVITAMINOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
HYPOVOLAEMIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
IMPAIRED FASTING GLUCOSE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
IRON DEFICIENCY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
KETOACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
LACTIC ACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
MALNUTRITION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
METABOLIC ACIDOSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
METABOLIC SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
OBESITY
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Metabolism and nutrition disorders
TYPE 1 DIABETES MELLITUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Metabolism and nutrition disorders
TYPE 2 DIABETES MELLITUS
|
0.39%
5/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Metabolism and nutrition disorders
VITAMIN B12 DEFICIENCY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Metabolism and nutrition disorders
VITAMIN D DEFICIENCY
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
2.9%
37/1296 • 5 years
|
2.0%
26/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHRITIS
|
0.77%
10/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ARTHROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
2.7%
35/1296 • 5 years
|
3.1%
40/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
BONE PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
BURSITIS
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CERVICAL SPINAL STENOSIS
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CHONDROCALCINOSIS PYROPHOSPHATE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CHONDROMALACIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
CHONDROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
COSTOCHONDRITIS
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
DUPUYTREN'S CONTRACTURE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
EXOSTOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FACET JOINT SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FEMOROACETABULAR IMPINGEMENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FLANK PAIN
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
FOOT DEFORMITY
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
GOUTY ARTHRITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
GROIN PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC COMPRESSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC DEGENERATION
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
INTERVERTEBRAL DISC PROTRUSION
|
0.46%
6/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
JOINT EFFUSION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
JOINT STIFFNESS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
JOINT SWELLING
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
LIMB DISCOMFORT
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
LUMBAR SPINAL STENOSIS
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MONARTHRITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE ATROPHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE NECROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
|
0.85%
11/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE TIGHTNESS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCLE TWITCHING
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULAR WEAKNESS
|
0.62%
8/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
|
0.93%
12/1296 • 5 years
|
1.3%
17/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL DISCOMFORT
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL PAIN
|
2.0%
26/1296 • 5 years
|
2.1%
27/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL STIFFNESS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MYALGIA
|
1.9%
24/1296 • 5 years
|
1.5%
19/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
MYOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
NECK PAIN
|
0.62%
8/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
NEUROPATHIC ARTHROPATHY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
RHEUMATOID ARTHRITIS
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
ROTATOR CUFF SYNDROME
|
0.93%
12/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SACROILIITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SCLERODERMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SENILE ANKYLOSING VERTEBRAL HYPEROSTOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL COLUMN STENOSIS
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPINAL OSTEOARTHRITIS
|
0.31%
4/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SPONDYLOLISTHESIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
SYNOVIAL CYST
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TENDONITIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TENOSYNOVITIS STENOSANS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
TRIGGER FINGER
|
0.15%
2/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Musculoskeletal and connective tissue disorders
VERTEBRAL FORAMINAL STENOSIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE MYELOID LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE PROMYELOCYTIC LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOCARCINOMA PANCREAS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE I
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-CELL LYMPHOMA STAGE IV
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BASAL CELL CARCINOMA
|
0.46%
6/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN BREAST NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN NEOPLASM OF BLADDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BENIGN SOFT TISSUE NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BILE DUCT CANCER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER CANCER
|
0.46%
6/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BLADDER NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BOWEN'S DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER
|
0.31%
4/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER IN SITU
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BREAST CANCER STAGE II
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
BRONCHIAL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CHRONIC LYMPHOCYTIC LEUKAEMIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON ADENOMA
|
0.46%
6/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
COLON CANCER
|
0.46%
6/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ENDOMETRIAL CANCER METASTATIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
FIBROMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GASTROINTESTINAL STROMAL TUMOUR
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MELANOCYTIC NAEVUS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HEPATIC NEOPLASM MALIGNANT RECURRENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
INTESTINAL ADENOCARCINOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LARYNGEAL CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LIPOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG ADENOCARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CANCER METASTATIC
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM
|
0.46%
6/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
|
0.54%
7/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LYMPHOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT GLIOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT MELANOMA IN SITU
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MALIGNANT PLEURAL EFFUSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MANTLE CELL LYMPHOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MENINGIOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO CENTRAL NERVOUS SYSTEM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTASES TO LIVER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC MALIGNANT MELANOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
METASTATIC RENAL CELL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MUELLER'S MIXED TUMOUR
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MULTIPLE MYELOMA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELODYSPLASTIC SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELOFIBROSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM MALIGNANT
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM OF APPENDIX
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEOPLASM SKIN
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NEUROENDOCRINE CARCINOMA METASTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-HODGKIN'S LYMPHOMA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NON-SMALL CELL LUNG CANCER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OESOPHAGEAL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OROPHARYNGEAL CANCER STAGE UNSPECIFIED
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER METASTATIC
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN CANCER STAGE III
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
OVARIAN NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC CARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PANCREATIC NEUROENDOCRINE TUMOUR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PARATHYROID TUMOUR BENIGN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PERITONEAL CARCINOMA METASTATIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PHAEOCHROMOCYTOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PITUITARY TUMOUR BENIGN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLASMACYTOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PLEURAL MESOTHELIOMA MALIGNANT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER
|
0.69%
9/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
PROSTATE CANCER METASTATIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL ADENOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RECTAL CANCER
|
0.23%
3/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CANCER
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
RENAL CELL CARCINOMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND CANCER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SALIVARY GLAND NEOPLASM
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SEBORRHOEIC KERATOSIS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SKIN CANCER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SMALL CELL LUNG CANCER STAGE UNSPECIFIED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
THYROID NEOPLASM
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRACHEAL CANCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
TRANSITIONAL CELL CARCINOMA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
URETERIC CANCER RECURRENT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
AMNESIA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
APHASIA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
BASAL GANGLIA INFARCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
BASILAR ARTERY STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
BRAIN INJURY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
BRAIN MASS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
BRAIN STEM INFARCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERIOSCLEROSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERY DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERY OCCLUSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CAROTID ARTERY STENOSIS
|
0.93%
12/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Nervous system disorders
CARPAL TUNNEL SYNDROME
|
0.62%
8/1296 • 5 years
|
0.69%
9/1308 • 5 years
|
|
Nervous system disorders
CENTRAL NERVOUS SYSTEM LESION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CEREBELLAR ATROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CEREBELLAR INFARCTION
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
CEREBRAL HAEMORRHAGE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
CEREBRAL INFARCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CEREBRAL SMALL VESSEL ISCHAEMIC DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CEREBROVASCULAR ACCIDENT
|
1.2%
15/1296 • 5 years
|
1.8%
23/1308 • 5 years
|
|
Nervous system disorders
CEREBROVASCULAR DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CERVICAL CORD COMPRESSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CERVICAL MYELOPATHY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CERVICOBRACHIAL SYNDROME
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
COGNITIVE DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
COMPLICATED MIGRAINE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
CONVULSION
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
CRANIAL NERVE DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
CUBITAL TUNNEL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DEMENTIA
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
DEMENTIA ALZHEIMER'S TYPE
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DEPRESSED LEVEL OF CONSCIOUSNESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
DIABETIC NEUROPATHY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
DIZZINESS
|
5.7%
74/1296 • 5 years
|
5.5%
72/1308 • 5 years
|
|
Nervous system disorders
DIZZINESS EXERTIONAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
DIZZINESS POSTURAL
|
1.1%
14/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Nervous system disorders
DRUG WITHDRAWAL HEADACHE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
DYSARTHRIA
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
DYSGEUSIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
EMBOLIC CEREBRAL INFARCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ENCEPHALOPATHY
|
0.54%
7/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
EPILEPSY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
ESSENTIAL TREMOR
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
FACIAL PARESIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
GRAND MAL CONVULSION
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
GUILLAIN-BARRE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
HAEMORRHAGE INTRACRANIAL
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
HAEMORRHAGIC STROKE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
HEAD DISCOMFORT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
HEAD TITUBATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
HEADACHE
|
1.8%
23/1296 • 5 years
|
2.1%
28/1308 • 5 years
|
|
Nervous system disorders
HEMIPARESIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
HYPERTONIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
INTERCOSTAL NEURALGIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
INTRACRANIAL ANEURYSM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
INTRAVENTRICULAR HAEMORRHAGE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ISCHAEMIC STROKE
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
LACUNAR INFARCTION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
LETHARGY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
LOSS OF CONSCIOUSNESS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
LUMBAR RADICULOPATHY
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
MEMORY IMPAIRMENT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
METABOLIC ENCEPHALOPATHY
|
0.46%
6/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
MIGRAINE
|
0.39%
5/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Nervous system disorders
MIGRAINE WITH AURA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
MONONEURITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
MULTIPLE SCLEROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
MUSCLE CONTRACTIONS INVOLUNTARY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
NERVE COMPRESSION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
NEURALGIA
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
NEURODEGENERATIVE DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
NEUROPATHY PERIPHERAL
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Nervous system disorders
PARAESTHESIA
|
2.2%
28/1296 • 5 years
|
1.8%
24/1308 • 5 years
|
|
Nervous system disorders
PARKINSON'S DISEASE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
PARTIAL SEIZURES
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
PRESYNCOPE
|
1.0%
13/1296 • 5 years
|
0.76%
10/1308 • 5 years
|
|
Nervous system disorders
RADIAL NERVE COMPRESSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
RADICULOPATHY
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
RESTLESS LEGS SYNDROME
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
SCIATICA
|
0.54%
7/1296 • 5 years
|
0.61%
8/1308 • 5 years
|
|
Nervous system disorders
SENSORY LOSS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
SOMNOLENCE
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Nervous system disorders
SUBARACHNOID HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Nervous system disorders
SYNCOPE
|
2.1%
27/1296 • 5 years
|
2.8%
36/1308 • 5 years
|
|
Nervous system disorders
TENSION HEADACHE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TOXIC ENCEPHALOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
|
1.2%
16/1296 • 5 years
|
1.1%
14/1308 • 5 years
|
|
Nervous system disorders
TREMOR
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TRIGEMINAL NEURALGIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
TYPICAL AURA WITHOUT HEADACHE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
ULNAR TUNNEL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Nervous system disorders
UNRESPONSIVE TO STIMULI
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
VERTEBRAL ARTERY STENOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Nervous system disorders
VIITH NERVE PARALYSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Pregnancy, puerperium and perinatal conditions
ABORTION SPONTANEOUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
ALCOHOL WITHDRAWAL SYNDROME
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
ANORGASMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
ANXIETY
|
1.5%
20/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Psychiatric disorders
ANXIETY DISORDER DUE TO A GENERAL MEDICAL CONDITION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
COMPLETED SUICIDE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
CONFUSIONAL STATE
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Psychiatric disorders
CONVERSION DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
DELIRIUM
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
DEPRESSION
|
0.62%
8/1296 • 5 years
|
0.92%
12/1308 • 5 years
|
|
Psychiatric disorders
DEPRESSION SUICIDAL
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
DISORIENTATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
IMPAIRED SELF-CARE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
INSOMNIA
|
0.54%
7/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Psychiatric disorders
INTENTIONAL SELF-INJURY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
MENTAL DISORDER DUE TO A GENERAL MEDICAL CONDITION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
MENTAL STATUS CHANGES
|
0.54%
7/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Psychiatric disorders
PANIC ATTACK
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Psychiatric disorders
PANIC DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
PERSONALITY DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
POST-TRAUMATIC AMNESTIC DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
PSYCHOGENIC PAIN DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Psychiatric disorders
SLEEP DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
SOMATOFORM DISORDER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
STRESS
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Psychiatric disorders
SUICIDAL IDEATION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
SUICIDE ATTEMPT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Psychiatric disorders
WITHDRAWAL SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
AZOTAEMIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER NECK OBSTRUCTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER OBSTRUCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER PERFORATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
BLADDER PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
CALCULUS BLADDER
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
CALCULUS URETERIC
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
CALCULUS URINARY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
CYSTITIS HAEMORRHAGIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
DYSURIA
|
0.39%
5/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
HAEMATURIA
|
0.85%
11/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Renal and urinary disorders
HYDRONEPHROSIS
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
HYPERTONIC BLADDER
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Renal and urinary disorders
NEPHROLITHIASIS
|
1.1%
14/1296 • 5 years
|
1.1%
15/1308 • 5 years
|
|
Renal and urinary disorders
NOCTURIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
OBSTRUCTIVE UROPATHY
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Renal and urinary disorders
POLLAKIURIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
POLYURIA
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
PROTEINURIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
RENAL ARTERY STENOSIS
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Renal and urinary disorders
RENAL COLIC
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
RENAL CYST
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Renal and urinary disorders
RENAL FAILURE
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
RENAL FAILURE ACUTE
|
2.5%
32/1296 • 5 years
|
2.2%
29/1308 • 5 years
|
|
Renal and urinary disorders
RENAL FAILURE CHRONIC
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Renal and urinary disorders
RENAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
RENAL IMPAIRMENT
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
RENAL MASS
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
RENAL PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
URETERIC STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URETHRAL MEATUS STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URINARY BLADDER POLYP
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URINARY HESITATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Renal and urinary disorders
URINARY INCONTINENCE
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.23%
3/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Renal and urinary disorders
URINARY TRACT OBSTRUCTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Renal and urinary disorders
URINE FLOW DECREASED
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
ACQUIRED HYDROCELE
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
ADNEXA UTERI MASS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
ATROPHIC VULVOVAGINITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
BENIGN PROSTATIC HYPERPLASIA
|
0.69%
9/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Reproductive system and breast disorders
BREAST PAIN
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
CYSTOCELE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
ENDOMETRIAL HYPERPLASIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
EPIDIDYMITIS
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Reproductive system and breast disorders
ERECTILE DYSFUNCTION
|
0.54%
7/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
GENITAL PAIN
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
GENITAL SWELLING
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
GYNAECOMASTIA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
MENORRHAGIA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
PELVIC PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
PENILE PAIN
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
PEYRONIE'S DISEASE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
PROSTATITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
PROSTATOMEGALY
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Reproductive system and breast disorders
SCROTAL CYST
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
UTERINE OBSTRUCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
UTERINE POLYP
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
VAGINAL HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Reproductive system and breast disorders
VAGINAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Reproductive system and breast disorders
VAGINAL PROLAPSE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Reproductive system and breast disorders
VULVAR DYSPLASIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACQUIRED DIAPHRAGMATIC EVENTRATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE INTERSTITIAL PNEUMONITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE PULMONARY OEDEMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY DISTRESS SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ACUTE RESPIRATORY FAILURE
|
1.2%
15/1296 • 5 years
|
1.4%
18/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ASPIRATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ASTHMA
|
0.77%
10/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
ATELECTASIS
|
0.23%
3/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
BRONCHITIS CHRONIC
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
BRONCHOSPASM
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
2.1%
27/1296 • 5 years
|
1.7%
22/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC RESPIRATORY FAILURE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
1.4%
18/1296 • 5 years
|
2.4%
32/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DIAPHRAGMATIC PARALYSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
12.3%
159/1296 • 5 years
|
12.8%
167/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA AT REST
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
|
4.5%
58/1296 • 5 years
|
5.0%
66/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
EMPHYSEMA
|
0.31%
4/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
|
1.6%
21/1296 • 5 years
|
1.2%
16/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HAEMOPTYSIS
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HAEMOTHORAX
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HICCUPS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
HYPOXIA
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
LUNG DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
LUNG INFILTRATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
NASAL SEPTUM DEVIATION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
NASAL TURBINATE HYPERTROPHY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
OBSTRUCTIVE AIRWAYS DISORDER
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL DISCOMFORT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL HYPERTROPHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PHARYNGEAL MASS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
0.54%
7/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL FIBROSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMONIA ASPIRATION
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMONITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
|
0.23%
3/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY CONGESTION
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY FIBROSIS
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY HYPERTENSION
|
0.31%
4/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY MASS
|
0.08%
1/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY OEDEMA
|
0.08%
1/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY TOXICITY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
REFLUX LARYNGITIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ALKALOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY ARREST
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY DISTRESS
|
0.23%
3/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY FAILURE
|
0.93%
12/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RESTRICTIVE PULMONARY DISEASE
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
RHINITIS ALLERGIC
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
SINUS CONGESTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
SLEEP APNOEA SYNDROME
|
0.46%
6/1296 • 5 years
|
0.99%
13/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
THROAT IRRITATION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
THROAT TIGHTNESS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
UPPER RESPIRATORY TRACT CONGESTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
VOCAL CORD POLYP
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Respiratory, thoracic and mediastinal disorders
WHEEZING
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ACNE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ACTINIC KERATOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ALOPECIA
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ANGIOEDEMA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
COLD SWEAT
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DECUBITUS ULCER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DERMAL CYST
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DERMATITIS
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DERMATITIS CONTACT
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DIGITAL ULCER
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DRUG ERUPTION
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
DRY GANGRENE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ECCHYMOSIS
|
0.08%
1/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
ERYTHEMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
HYPERHIDROSIS
|
1.6%
21/1296 • 5 years
|
1.8%
23/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
INCREASED TENDENCY TO BRUISE
|
0.31%
4/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
INGROWING NAIL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
LEUKOCYTOCLASTIC VASCULITIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
LICHEN SCLEROSUS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
LIVEDO RETICULARIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
NIGHT SWEATS
|
0.23%
3/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PETECHIAE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PRECANCEROUS SKIN LESION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PRURITUS
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PRURITUS ALLERGIC
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
PSORIASIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
RASH
|
1.0%
13/1296 • 5 years
|
0.38%
5/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
RASH GENERALISED
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
RASH MACULAR
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
RASH PRURITIC
|
0.31%
4/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SCAR PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SKIN DISCOLOURATION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SKIN FISSURES
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SKIN LESION
|
0.15%
2/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SKIN ULCER
|
0.23%
3/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SWELLING FACE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
SYSTEMIC LUPUS ERYTHEMATOSUS RASH
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Skin and subcutaneous tissue disorders
URTICARIA
|
0.39%
5/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Social circumstances
MENOPAUSE
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Social circumstances
PHYSICAL ASSAULT
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Social circumstances
TREATMENT NONCOMPLIANCE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
ABSCESS DRAINAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
AORTIC STENT INSERTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
BAKER'S CYST EXCISION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
CARDIAC PACEMAKER BATTERY REPLACEMENT
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Surgical and medical procedures
CATARACT OPERATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
CORONARY ARTERIAL STENT INSERTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
FRACTURE REDUCTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
HERNIA REPAIR
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
HIP ARTHROPLASTY
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
HYSTERECTOMY
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
IMPLANTABLE DEFIBRILLATOR INSERTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
KNEE ARTHROPLASTY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
NASAL OPERATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
NECK SURGERY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
PERCUTANEOUS CORONARY INTERVENTION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Surgical and medical procedures
ROTATOR CUFF REPAIR
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Surgical and medical procedures
SURGERY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ACCELERATED HYPERTENSION
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
AORTIC ANEURYSM
|
0.15%
2/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Vascular disorders
AORTIC DISSECTION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
AORTIC INTRAMURAL HAEMATOMA
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
AORTIC STENOSIS
|
0.31%
4/1296 • 5 years
|
0.31%
4/1308 • 5 years
|
|
Vascular disorders
ARTERIAL DISORDER
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ARTERIAL HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIAL OCCLUSIVE DISEASE
|
0.08%
1/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIAL SPASM
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
ARTERIAL THROMBOSIS LIMB
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIOSCLEROSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ARTERIOVENOUS FISTULA
|
0.08%
1/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
DEEP VEIN THROMBOSIS
|
0.54%
7/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Vascular disorders
EMBOLISM ARTERIAL
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ESSENTIAL HYOERTENSION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERIAL STENOSIS
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY ANEURYSM
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY DISSECTION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
FEMORAL ARTERY OCCLUSION
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
HAEMATOMA
|
0.62%
8/1296 • 5 years
|
0.92%
12/1308 • 5 years
|
|
Vascular disorders
HAEMORRHAGE
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
HOT FLUSH
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
HYPERTENSION
|
4.2%
55/1296 • 5 years
|
5.3%
69/1308 • 5 years
|
|
Vascular disorders
HYPERTENSIVE CRISIS
|
1.0%
13/1296 • 5 years
|
0.84%
11/1308 • 5 years
|
|
Vascular disorders
HYPERTENSIVE EMERGENCY
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
HYPOTENSION
|
2.9%
38/1296 • 5 years
|
2.2%
29/1308 • 5 years
|
|
Vascular disorders
HYPOVOLAEMIC SHOCK
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ILIAC ARTERY OCCLUSION
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ILIAC ARTERY STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
INTERMITTENT CLAUDICATION
|
0.77%
10/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Vascular disorders
INTRA-ABDOMINAL HAEMATOMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
ISCHAEMIC LIMB PAIN
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
LERICHE SYNDROME
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
LYMPHOEDEMA
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
MACROANGIOPATHY
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
MALIGNANT HYPERTENSION
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
ORTHOSTATIC HYPOTENSION
|
0.62%
8/1296 • 5 years
|
0.54%
7/1308 • 5 years
|
|
Vascular disorders
PELVIC VENOUS THROMBOSIS
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
|
0.69%
9/1296 • 5 years
|
1.2%
16/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL COLDNESS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL ISCHAEMIA
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
PERIPHERAL VASCULAR DISORDER
|
0.39%
5/1296 • 5 years
|
0.46%
6/1308 • 5 years
|
|
Vascular disorders
REPERFUSION INJURY
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
SHOCK
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
THROMBOPHLEBITIS
|
0.00%
0/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
THROMBOPHLEBITIS SUPERFICIAL
|
0.00%
0/1296 • 5 years
|
0.23%
3/1308 • 5 years
|
|
Vascular disorders
THROMBOSIS
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VARICOSE VEIN
|
0.15%
2/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VASCULAR STENOSIS
|
0.00%
0/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
VASOSPASM
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
|
Vascular disorders
VENOUS INSUFFICIENCY
|
0.15%
2/1296 • 5 years
|
0.15%
2/1308 • 5 years
|
|
Vascular disorders
VENOUS RECANALISATION
|
0.08%
1/1296 • 5 years
|
0.00%
0/1308 • 5 years
|
|
Vascular disorders
VENOUS THROMBOSIS LIMB
|
0.15%
2/1296 • 5 years
|
0.08%
1/1308 • 5 years
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60